Inflammatory Myopathies

The idiopathic inflammatory myopathies are a heterogeneous group of autoimmune diseases in which immune-mediated injury to skeletal muscle produces muscle weakness, often accompanied by characteristic skin, lung, and joint involvement. The principal subtypes include dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, the antisynthetase syndrome, and inclusion body myositis, each with distinct clinical, pathological, and serologic features.

Definition

The idiopathic inflammatory myopathies are autoimmune disorders characterized by inflammation of skeletal muscle leading to proximal muscle weakness and elevated muscle enzymes, frequently associated with extramuscular features and myositis-specific or myositis-associated autoantibodies.

Scope

This entry covers the inflammatory myopathies as a clinical group within the systemic autoimmune diseases: the immune mechanisms of muscle injury, the major clinicopathological subtypes, the role of myositis-specific autoantibodies, and how classification criteria define study populations. It is reference-educational and does not provide diagnostic or treatment instructions.

Key concepts

• Proximal symmetric muscle weakness
• Dermatomyositis and its cutaneous signs
• Polymyositis
• Immune-mediated necrotizing myopathy
• Antisynthetase syndrome
• Inclusion body myositis
• Myositis-specific autoantibodies
• Interstitial lung disease association

Mechanisms

The inflammatory myopathies share immune-mediated muscle injury but differ in pathway. Dermatomyositis is associated with a humoral and complement-mediated microangiopathy and a prominent type I interferon signature affecting muscle and skin, whereas polymyositis and inclusion body myositis feature cytotoxic T-cell-mediated attack on muscle fibers; immune-mediated necrotizing myopathy shows prominent fiber necrosis with relatively sparse inflammation. Myositis-specific autoantibodies define clinically meaningful subsets and correlate with patterns of skin, lung, and malignancy risk (Dalakas, 2015). Inclusion body myositis additionally shows degenerative features and characteristically responds poorly to immunosuppression.

Clinical relevance

The inflammatory myopathies illustrate how autoimmunity can target skeletal muscle while also producing systemic features such as interstitial lung disease and, in dermatomyositis, an association with underlying malignancy. Classification criteria such as the 2017 EULAR/ACR criteria define consistent research populations rather than diagnose individuals (Lundberg et al., 2017). This entry describes the diseases conceptually and is not a basis for individual diagnostic or therapeutic decisions.

Epidemiology

The idiopathic inflammatory myopathies are rare, with dermatomyositis and polymyositis showing a female predominance and onset across childhood and adulthood, while inclusion body myositis typically affects older adults, more often men. Specific incidence and prevalence vary by subtype and population (Dalakas, 2015).

Evidence & guidelines

Classification for research has moved from the historically influential Bohan and Peter criteria (Bohan & Peter, 1975) to the data-driven 2017 EULAR/ACR criteria, which combine clinical, laboratory, and muscle-biopsy items and incorporate anti-Jo-1 antibody status (Lundberg et al., 2017). These criteria standardize study populations and are distinct from clinical diagnosis; serologic and biopsy-based subtyping has refined the modern classification.

History

Bohan and Peter's 1975 description provided the first widely used framework for classifying polymyositis and dermatomyositis (Bohan & Peter, 1975). Subsequent recognition of immune-mediated necrotizing myopathy, the antisynthetase syndrome, and inclusion body myositis, together with the discovery of an expanding panel of myositis-specific autoantibodies, reshaped the field and culminated in the 2017 EULAR/ACR classification criteria.

Debates

How should the inflammatory myopathies be subclassified?

Whether classification should rest primarily on clinical phenotype, muscle histopathology, or myositis-specific autoantibody profiles remains debated, and serology-based subsetting increasingly competes with traditional clinicopathological categories.

Key figures

• Marinos Dalakas
• Ingrid Lundberg
• Anthony Bohan
• James Peter

Seminal works

• dalakas-2015
• lundberg-2017
• bohan-peter-1975

Frequently asked questions

What distinguishes dermatomyositis from polymyositis?

Dermatomyositis features characteristic skin findings and a microvascular, complement-mediated muscle pathology, whereas polymyositis lacks the typical rash and is associated with a cytotoxic T-cell-mediated attack on muscle fibers.

Why are myositis-specific autoantibodies emphasized?

They define clinically meaningful subgroups that correlate with patterns of muscle, skin, and lung involvement and with associated risks, helping characterize the inflammatory myopathies.